SCHEMBL1765207

SCHEMBL1765207

Fc1cccc(-c2cnc(C3CC3)s2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.46
HSD17B1 P14061 2/20 0.43
HSD17B2 P37059 2/20 0.43
QPCT Q16769 2/20 0.40
FYN P06241 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
MAP4K3 Q8IVH8 3/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
IDO1 P14902 2/20 0.37
TDO2 P48775 2/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403445 0.84 SLC6A2 (0.47) MLYCDQPCTMAP4K3SLC6A2SLC6A4
SCHEMBL29786817 0.84 KDR (0.46) LOXL2TRPV1SLC6A2SLC6A4SLC6A3
SCHEMBL20924388 0.82 HSD17B1 (0.60) HSD17B1HSD17B2FYNCYP3A4CYP2C9
SCHEMBL30866470 0.82 MAP4K4 (0.45) MLYCDHSD17B1HSD17B2QPCTLOXL2
SCHEMBL20500609 0.82 MAP4K4 (0.45) MLYCDHSD17B1HSD17B2QPCTLOXL2
SCHEMBL2404693 0.82 SLC6A2 (0.51) HSD17B1HSD17B2QPCTLOXL2MAP4K3
SCHEMBL26255820 0.78 KDR (0.44) LOXL2MAP4K3TRPV1SLC6A2SLC6A4
SCHEMBL4677035 0.75 KDR (0.41) MLYCDLOXL2TRPV1SLC6A2SLC6A4
SCHEMBL17151793 0.75 MAP4K3 (0.48) MAP4K3SLC6A2SLC6A4SLC6A3
SCHEMBL9955397 0.74 HSD17B1 (0.47) HSD17B1HSD17B2LOXL2KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CNR1 MLYCD 4226/4885HSD17B1 882/4885HSD17B2 782/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 MLYCD 3700/4885HSD17B1 3718/4885HSD17B2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.